Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00688
|
|||||
| Drug Name |
Gemifloxacin
|
|||||
| Synonyms |
7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; Factiv; Factiv (TN); Factive; Factive (TN); Gemifloxacin (INN); Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; LB-20304; SB 265805; SB-265805
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Bacterial infections [ICD11:1A00-1H0Z] | Approved | [1] | |||
| Therapeutic Class |
Antibiotics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C18H20FN5O4
|
|||||
| Canonical SMILES |
CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F
|
|||||
| InChI |
InChI=1S/C18H20FN5O4/c1-28-22-14-8-23(6-9(14)5-20)17-13(19)4-11-15(25)12(18(26)27)7-24(10-2-3-10)16(11)21-17/h4,7,9-10H,2-3,5-6,8,20H2,1H3,(H,26,27)/b22-14+
|
|||||
| InChIKey |
ZRCVYEYHRGVLOC-HYARGMPZSA-N
|
|||||
| CAS Number |
CAS 175463-14-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 389.4 | Topological Polar Surface Area | 121 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 5 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 10 | |||
| XLogP |
-0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103165376
,104064190
,124766444
,126665045
,131302500
,134338130
,135029930
,137267488
,141952322
,14878468
,152047100
,162263733
,163384560
,172861476
,175438039
,179150073
,223664023
,226504227
,238411063
,23996711
,251890177
,251963973
,252358754
,44709303
,46507905
,48395332
,50070532
,50071315
,50123382
,57372939
,610685
,79751939
,85305864
,85789646
,91613407
,96024705
|
|||||
| ChEBI ID |
CHEBI:101853
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
| References | ||||||
| 1 | Gemifloxacin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin. Int J Pharm. 2011 Nov 25;420(1):26-33. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.